When the Oncologist Becomes the Cancer Patient

Article

An interesting interview aired yesterday on NPR's Fresh Air. During a routine mammogram on Dr Marisa Weiss, a breast cancer oncologist and founder of breastcancer.org, a tumor was discovered.

An interesting interview with Dr Marisa Weiss, a breast cancer oncologist and founder of breastcancer.org, aired yesterday on NPR's Fresh Air. At age 50 doctors discovered a tumor in her breast during a routine mammogram. Their conversation jumps from her personal experience as a patient and doctor to the latest issues in the field of oncology.

Here is Dr Weiss on mammograms:

"I believe strongly that women should get their first mammogram starting at age 40 and have it each year after that - and start even earlier if they're at higher risk. The taskforce guidelines that came out in November of 2009 recommend that women start getting mammograms at age 50 and then do it every other year. And they base that on old-fashioned studies using old-fashioned technology: film mammography instead of what we have today which is digital mammography. And they use that old-fashioned literature to make futuristic predictions."

Click the link below to read more or to listen to the full interview:
A Breast Oncologist, Diagnosed With The Disease

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.